AshkanEmadiMDPhD

Hematologic Oncology, Clinical Pharmacology

Professor of Medicine and Pharmacology at University of Maryland School of Medicine; Associate Director for Clinical Research Greenebaum Comprehensive Cancer Center; Director Translational Genomics Laboratory

Join to view full profile

Dr. Emadi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Emadi's full profile

Already have an account?

Office
22 S Greene St
N9E24
Baltimore, MD 21201
Phone+1 410-328-2596

Fax+1 410-328-6896
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2005 - 2007
University of Kentucky College of MedicineInternship, Internal Medicine, 2004 - 2005
Illinois Institute of TechnologyPhD, Organic Chemistry, 2000 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2006 - 2024
WV State Medical License 2024 - 2024
OH State Medical License 2005 - 2007
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2012 Jan 13
Completed
Phase 1
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) Start of enrollment: 2014 Apr 01
Completed
Phase 1
Trial of Imatinib for Hospitalized Adults With COVID-19 Start of enrollment: 2020 Jun 02
Active, not recruiting
Phase 3
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Start of enrollment: 2021 Mar 10
Active, not recruiting
Phase 1
Roles: Principal Investigator
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL Start of enrollment: 2021 Jun 11
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia.
Max An, Christine Dougherty, Yamini K Kathari, Ashkan Emadi> ;Pharmaceuticals. 2024 Mar 5
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
Gabriela Sanchez-Petitto, Olga G Goloubeva, Jack Masur, James Childress, Tahreem Iqbal, Max An, Safwan Muhammad, Justin Lawson, Grace Li, Brian Barr, Ashkan Emadi, Jen...> ;Leukemia Research. 2024 Mar 1
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman, J., Zuckerman, T., Koprivnikar, J., McCloskey, J., Kota, V., Keng, M., Frankfurt, O., Abaza, Y., Bixby, D., Emadi, A., Burch, M., Bhatnagar, B., Luger, S., Per...> ;Blood Advances. 2023 Dec 26
Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Zhang, Y., Kallen, M., Ning, Y., Emadi, A., Baer, M.> ;Best Practice & Research. Clinical Haematology. 2023 Dec 1
Olanzapine within steroid-sparing antiemetic regimen to prevent chemotherapy-induced nausea and vomiting in patients with acute leukemia receiving multi-day intensive ...
Grace Hsu, Ciera Bernhardi, Justin Lawson, Vu H Duong, Ashkan Emadi, Sandrine Niyongere, Alison Duffy> ;Journal of Oncology Pharmacy Practice. 2023 Oct 10
Community-engaged basic science in an NCI-designated comprehensive cancer center: antioxidants and chemotherapeutic efficacy.
Dominique Bollino, Nathaniel Woodard, Kayla M Tighe, Xinrong Ma, Andrea Casildo, Christopher R D'Adamo, Ashkan Emadi, Cheryl L Knott> ;Cancer Causes & Control. 2024 Mar 1
Impact of pegaspargase dose capping on incidence of pegaspargase-related adverse events in adults.
Emily Tiao, Ciera L Bernhardi, James A Trovato, Justin Lawson, Hyunuk Seung, Ashkan Emadi, Alison P Duffy> ;Journal of Oncology Pharmacy Practice. 2023 Sep 20
4 citations
Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.
Gautam Adhikary, Suruchi Shrestha, Warren Naselsky, John J Newland, Xi Chen, Wen Xu, Ashkan Emadi, Joseph S Friedberg, Richard L Eckert> ;Molecular Carcinogenesis. 2023 Apr 1
Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse populat...
Stacey Doran, Manu Mysore, Seyed Ebrahim Kassaian, Ethan Kotloff, Farin Kamangar, Ashkan Emadi, Jummai Apata, Brian Barr> ;Frontiers in Cardiovascular Medicine. 2023 Jan 1
4 citations
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H Duong, Patricia Kropf, Jakob Werner Hansen, Denice Tsao-Wei, Hyo Sik Jang, Ashkan Emadi, S...> ;Clinical Cancer Research. 2022 Dec 15
1 citations
Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype andR132C mutation.
Hanan Alkhaldi, Danielle Sewell, Yi Ning, Michael E Kallen, Ashkan Emadi, Nancy M Hardy, Maria R Baer> ;Leukemia & Lymphoma. 2022 Dec 1
3 citations
Impact of-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.
Elizabeth M Corley, Moaath K Mustafa Ali, Hanan Alharthy, Kathryn A F Kline, Danielle Sewell, Jennie Y Law, Seung Tae Lee, Sandrine Niyongere, Vu H Duong, Maria R Baer...> ;Biology. 2022 Jun 15
15 citations
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Maria R Baer, Aksinija A Kogan, Søren M Bentzen, Tian Mi, Rena G Lapidus, Vu H Duong, Ashkan Emadi, Sandrine Niyongere, Casey L O'Connell, Benjamin A Youngblood, Steph...> ;Clinical Cancer Research. 2022 Apr 1
2 citations
Translatome changes in acute myeloid leukemia cells post exposure to pegcrisantaspase and venetoclax.
Bandish Kapadia, Amol C Shetty, Dominique Bollino, Binny Bhandary, Rena G Lapidus, Kanwal Mahmood, Anup Mahurkar, Ronald B Gartenhaus, Richard L Eckert, Ashkan Emadi> ;Experimental Hematology. 2022 Apr 1
3 citations
Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.
Elizabeth M Corley, Moaath K Mustafa Ali, Hanan Alharthy, Kathryn A F Kline, Danielle Sewell, Jennie Y Law, Seung Tae Lee, Sandrine Niyongere, Vu H Duong, Maria R Baer...> ;Frontiers in Oncology. 2022 Jan 1
7 citations
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Moaath K Mustafa Ali, Elizabeth M Corley, Hanan Alharthy, Kathryn A F Kline, Jennie Y Law, Seung Tae Lee, Sandrine Niyongere, Vu H Duong, Ashkan Emadi, Maria R Baer> ;Frontiers in Oncology. 2022 Jan 1
Therapy-related B-lymphoblastic leukemia after multiple myeloma.
Michael E Kallen, Rima Koka, Zeba N Singh, Yi Ning, Mehmet H Kocoglu, Ashraf Z Badros, Sandrine Niyongere, Vu H Duong, Ashkan Emadi, Maria R Baer> ;Leukemia Research Reports. 2022 Jan 1
Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine.
Dominique Bollino, J Preston Claiborne, Kanwal Hameed, Xinrong Ma, Kayla M Tighe, Brandon Carter-Cooper, Rena G Lapidus, Erin T Strovel, Ashkan Emadi> ;Frontiers in Oncology. 2022 Jan 1
5 citations
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Kyle Zacholski, Bryan C. Hambley, Erin Hickey, Sarah M. Kashanian, Andrew Y. Li, Maria R. Baer, Vu H. Duong, Matthew J Newman, Amy E. DeZern, Ivana Gojo, B. Douglas Sm...> ;Journal of Oncology Pharmacy Practice. 2021 Jun 17
1 citations
Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia.
Dana Ferraris, Rena G. Lapidus, Phuc Huu Truong, Dominique Bollino, Brandon Carter-Cooper, Michelle Lee, Elizabeth T. Chang, Maria LaRossa-Garcia, Smaraki Dash, Ronald...> ;Anti-Cancer Agents in Medicinal Chemistry. 2021 Jun 2
1 citations
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-...
Meagan A. Jacoby, Laura Finn, Ashkan Emadi, Nakhle S. Saba, Bayard L. Powell, Karen Seiter, Rosella Garcia, Stefan Faderl, Heather Male> ;Leukemia & Lymphoma. 2021 May 11
7 citations
Risks and benefits of antioxidant dietary supplement use during cancer treatment: protocol for a scoping review.
L. Susan Wieland, Ilana M. Moffet, Sydney Shade, Ashkan Emadi, Cheryl L. Knott, Emily F. Gorman, Christopher R. D'Adamo> ;BMJ Open. 2021 Apr 13
2 citations
FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
Andrew Y. Li, Sarah M. Kashanian, Bryan C. Hambley, Kyle Zacholski, Vu H. Duong, Firas El Chaer, Noa G. Holtzman, Ivana Gojo, Jonathan Webster, Kelly J. Norsworthy, B ...> ;Biology. 2021 Mar 21
3 citations
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens
Sarah M. Kashanian, Noa G. Holtzman, Ciera L Patzke, Jonathan Cornu, Alison Duffy, Madhurima Koka, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Jummai Apata, Farin ...> ;Cancer Chemotherapy and Pharmacology. 2021 Mar 7
7 citations
1-C Metabolism-Serine, Glycine, Folates-In Acute Myeloid Leukemia.
Kanwal Mahmood, Ashkan Emadi> ;Pharmaceuticals. 2021 Feb 26
Join now to see all

Abstracts/Posters

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Ashkan Emadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
$50 Million Gift Will Spur Development of Morgantown Cancer CenterApril 7th, 2024